REVANCE THERAPEUTICS, INC.
RVNC US7613301099
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -40% | 8% | -52% | -67% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Hollander David CMO |
4.17 USD |
3,908 Sold |
16,296 USD |
18/11/2024 | 18/11/2024 |
| Hollander David CMO |
4.17 USD |
3,908 Sold |
16,296 USD |
18/11/2024 | 18/11/2024 |
| Jordan Erica CCO |
3.80 USD |
2,392 Sold |
9,096 USD |
16/04/2024 | 16/04/2024 |
| Moxie Dwight CLO |
5.04 USD |
8,125 Sold |
40,971 USD |
15/03/2024 | 18/03/2024 |
| Sjuts Dustin S PR |
5.04 USD |
9,211 Sold |
46,446 USD |
15/03/2024 | 18/03/2024 |
| Schilke Tobin CFO |
5.04 USD |
9,361 Sold |
47,204 USD |
15/03/2024 | 18/03/2024 |
| Foley Mark J CEO |
6.98 USD |
30,000 Bought |
209,400 USD |
06/03/2024 | 06/03/2024 |